The MedTech Dive Outlook on 2021

Kendall Davis/MedTech Dive, original photos courtesy of Abbott and Dexcom

Note from the editor

How soon will elective surgeries, on which many medtechs depend for a big chunk of revenue, approach levels seen before the pandemic? Many observers see a late 2020 surge in COVID-19 cases pushing any comeback to the second half of 2021. COVID-19 tests have buoyed companies like Abbott, Hologic and Roche during the crisis, but a vaccine will inevitably lessen demand -- by how much and how fast is uncertain. The year is off to a brisk start on the M&A front, but what are the prospects for the remaining months? These are among the questions we explore in MedTech Dive’s trends to watch in 2021.

This year could also be seminal for continuous glucose monitors and insulin pumps, with a trend toward wearables and remote patient monitoring supercharged by the pandemic. Smaller players Insulet and Dexcom will be competing in a market with giants like Medtronic and Abbott, with several companies prepping big product launches.

Finally, the TAVR market has been fast-growing in recent years, with Edwards and Abbott among those selling devices pegged as a less invasive alternative to open-heart surgery. For the year ahead, industry has its eyes on mitral replacement and repair, seen as a multibillion dollar opportunity with a larger potential patient population that’s largely untapped.

Happy New Year and thanks for reading.

Kim Dixon Lead Editor

4 key trends for medtech in 2021

COVID-19 challenges, and opportunities, will continue to impact companies this year.

• Published Jan. 29, 2021

CGM, insulin pump players look to 2021 as watershed year for diabetes wearables market

Insulet, Dexcom and Medtronic have product launches planned this year, looking to capitalize on the recent skyrocketing of virtual care due to the coronavirus pandemic.

• Published Jan. 29, 2021

Abbott, Edwards focus on mitral valve as market projected to rival TAVR

Companies have recently had all eyes on TAVR in recent years, but in 2021 and beyond, industry is looking to the mitral market for the next big structural heart splash.

• Published Jan. 25, 2021

The MedTech Dive Outlook on 2021

The pandemic will keep disrupting the industry in the year ahead, as COVID-19 testing wanes and elective procedures slowly ease back. We look at the risks, challenges and opportunities.

included in this trendline
  • 4 key trends medtech professionals should watch
  • How 2021 could be a watershed year for the diabetes wearables market
  • Why the industry is looking to the mitral market for the next big structural heart splash
Note: Trendlines are a premium product, available to subscribers of our free newsletters. Access this Trendline by signing up for the Medtech Dive newsletter or enter your information if you're already subscribed.
Produced by our team of award-winning journalists, these Outlooks can help businesses navigate the uncertain road ahead in 2021.
Davide Savenije Editor-in-Chief at Industry Dive.